Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and closely interconnected to the metabolic syndrome. Liver-specific and systemic signaling pathways orchestrating glucose and fatty acid metabolism contribute to intrahepatic accumulation of lipids and inflammatory processes eventually causing disease progression to nonalcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. Since a high number of key regulatory genes regarding liver homeostasis are directly mediated via thyroid hormone (TH) signaling, targeting TH receptors (TRs) represent a promising therapeutic potential for the treatment of NAFLD. AREAS COVERED: In this review, we elucidate the effects of TH on metabolic regulations in the liver via local availability and actions. We discuss recent advances and the potential impact of thyromimetics in basic research and clinical trials including liver-targeted and TRβ-specific agents for the treatment of NAFLD. EXPERT OPINION: Unselective TR targeting can be accompanied by negative side effects due to high TRβ expression in other organs and TRα-mediated effects. Recent advances in drug development and the introduction of liver-targeted thyromimetics selectively activating TRβ such as Resmetirom (MGL-3196) and VK2809 bring new hope of translating the knowledge on local TH effects into effective hepatic lipid-clearing therapies against NASH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), FXR and THR (particularly THR-β) are the most extensively studied receptors that are targets for therapy.20–22”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [21]
In the citing paper
“For THR agonists and thyromimetics, THR-α stimulation has an antifibrotic effect on HSCs, suggesting that the fibrosis improvement in patients treated with the THR-β agonist resmetirom is more likely a consequence of reduced metabolic injury.21”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [21]
In the citing paper
“For THR agonists and thyromimetics, THR-α stimulation has an antifibrotic effect on HSCs, suggesting that the fibrosis improvement in patients treated with the THR-β agonist resmetirom is more likely a consequence of reduced metabolic injury.21”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [21]
Citations
Cites
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) already represents the most common cause of chronic liver disease, and its prevalence is expected to rise further in the near future [1,2].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 1×
“meaning elucidation of pathomechanistic insights, identification of new potential compounds, and combination of different drug targets – is of utmost importance [82,83].”
BackgroundEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Self-citation
Research works printed but not linked: 10
- Hönes GS, 2020, Exp Clin Endocrinol Diabetes, 128, 383
- Magnus-Levy A, 1895, Berlin Klin Wochenschr, 32, 650
- Magnus-Levy A, 1896, Verhandl. D XIV Kongr. F Inn. Med. S, 140
- Pazos F, 1995, J Clin Endocrinol Metab, 80, 562
- Tzouvelekis A, 2016, Eur Respir J, 48, A780
- Papatheodorou I, 2020, Nucleic Acids Res, 48, D77
- Renko K, 2019, Thyroid, 29, A-177-A
- Göhmann PJ, 2019, 42nd Annual Meeting of the European Thyroid Association
- 10.1089/thy.2019.29087 · doi:10.1089/thy.2019.29087
- 10.1016/j.cgh.2021.07.039 · DOI
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“Antifibrotic effects have also been reported for THR stimulation, and thyromimetic agents, which can be used to treat dyslipidaemia, are currently in clinical development for the treatment of NASH 241 .”
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 181
“Selective THR-β agonists improve the conversion of T4 to T3 and likely enhance mitochondrial function, besides the anticipated beneficial metabolic effects [310–312].”
Background
Metadata
- Authors
- Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F.
- Affiliations
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Tacke, Frank
- Venue
- Expert Review of Endocrinology & Metabolism
- Publisher
- Informa UK Limited
- Published
- 2022-08-11
- Volume
- 17
- Issue
- 5
- Pages
- 425-434
- ISSN
- 1744-6651 (ISSN-L)
- 1744-8417
- OpenAlex
- W4290182828
- Cited by
- 42
- References
- 107
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 20 · 2023: 8 · 2022: 1
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- German Research Foundation (DFG SFB/TRR 296 and CRC 1382, Project-ID 403224013)
- Berlin Institute of Health (BIH) Clinician Scientist Program
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- thyroid hormones, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, thyroid hormone receptor, resmetirom, thyromimetics, hepatic lipid accumulation, liver fibrosis, metabolic syndrome
- MeSH terms
- Humans, Thyroid Hormones, Disease Progression, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1080/17446651.2022.2110864
- The paper
- Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022). Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. Expert Review of Endocrinology & Metabolism. https://doi.org/10.1080/17446651.2022.2110864
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.